Abstract 3387
Background
Patients undergoing haematopoietic stem cell transplantation (HSCT) are often hospitalised in protective isolation in order to reduce the risk of dangerous infection. However, they could experience isolation-related suffering, problems in relationships with others, and difficulties in relating to themselves. Oncology nurses might play an important role in mitigating perceived isolation and in providing emotional support. The aim of this study was to identify which factors can influence the level of emotional support from nurses perceived by patients with haematological malignancies undergoing HSCT in isolation.
Methods
A multicentre prospective study was conducted in 10 haematology centres of the Italian Group of stem cell transplant (GITMO). Emotional support from nurses was measured between day +7 and +9 post-transplant using the Scale Experiences on the Newcastle Satisfaction with Nurses Scale. Multiple linear regression analysis was performed.
Results
The participants were 186 adult patients receiving autologous (48%) or allogeneic (52%) HSCT in protective isolation. They were mainly male (61.6%) with a mean age of 50.1 (SD = 13.4; range=19-71). The regression model explained 23% of the total variance (p < .001) (Table). Sex, pain level, double room, satisfaction with information received before HSCT, and patients to nurse ratio were independently associated with emotional support from nurses.Table: CN56
Regression model predicting perceived emotional support from nurses (n = 186)
β | 95% CI | P | |
---|---|---|---|
Sex (female) | .193 | (.056; .332) | .006 |
Pain level | -.147 | (-.287; -.007) | .040 |
First HSCT | .099 | (-.038; .234) | .158 |
Double room | .242 | (.098; .378) | .001 |
Satisfaction with info | .403 | (.264; .547) | <.001 |
Patients to nurse | -.168 | (-.316; -.027) | .021 |
P | <.001 |
Conclusions
Patients who reported high emotional support from nurses were female, with low pain, satisfied with information received, and hospitalised in double room in a ward with a low patients to nurse ratio. It is crucial to reduce the patients to nurse ratio in order to promote the role of nurses in providing emotional support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Campus Bio-Medico di Roma University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract